The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study

Efficacy And Safety ◽

Double Blind ◽

Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2013.12.1068 ◽

2014 ◽

Vol 133 (2) ◽

pp. AB404 ◽

Cited By ~ 2

Author(s):

Thomas R.M. Bieber ◽

Diamant Thaci ◽

Neil Graham ◽

Gianluca Pirozzi ◽

Ariel Teper ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Double Blind ◽

Exploring the efficacy and safety of topical Jaungo application in patients with atopic dermatitis: A pilot randomized, double-blind, placebo-controlled study

Complementary Therapies in Medicine ◽

10.1016/j.ctim.2018.07.007 ◽

2018 ◽

Vol 40 ◽

pp. 22-28 ◽

Cited By ~ 1

Author(s):

Jin Hyang Ahn ◽

Younghee Yun ◽

Min Hee Kim ◽

Seoung-Gyu Ko ◽

Kyu Seok Kim ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

The oral Janus kinase/spleen tyrosine kinase inhibitorASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

British Journal of Dermatology ◽

10.1111/bjd.17932 ◽

2019 ◽

Vol 181 (4) ◽

pp. 733-742 ◽

Cited By ~ 28

Author(s):

R. Bissonnette ◽

C. Maari ◽

S. Forman ◽

N. Bhatia ◽

M. Lee ◽

...

Keyword(s):

Atopic Dermatitis ◽

Tyrosine Kinase ◽

Systemic Inflammation ◽

Janus Kinase ◽

Controlled Study ◽

Spleen Tyrosine Kinase ◽

Double Blind ◽

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study

Osteoarthritis and Cartilage ◽

10.1016/j.joca.2016.12.025 ◽

2017 ◽

Vol 25 (6) ◽

pp. 832-838 ◽

Cited By ~ 18

Author(s):

G. Wang ◽

L. Bi ◽

X. Li ◽

Z. Li ◽

D. Zhao ◽

...

Keyword(s):

Chronic Pain ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727446943.793555535 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Phase Ii Study ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study

Endocrinology Diabetes & Metabolism ◽

10.1002/edm2.222 ◽

2021 ◽

Author(s):

Linong Ji ◽

Ling Li ◽

Jianhua Ma ◽

Xuefeng Li ◽

Dongmei Li ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Efficacy and safety of topical OPA ‐15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double‐blind, placebo‐controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.14979 ◽

2019 ◽

Vol 46 (8) ◽

pp. 672-679 ◽

Cited By ~ 3

Author(s):

Hidehisa Saeki ◽

Makoto Kawashima ◽

Satoko Sugaya ◽

Kazuhide Oshiden ◽

Hidetsugu Tsubouchi ◽

...

Keyword(s):

Atopic Dermatitis ◽

Japanese Patients ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase III, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.737 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB199

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Japanese Adult ◽

Double Blind ◽

Janus Kinase Inhibitor

Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study

British Journal of Dermatology ◽

10.1111/bjd.15493 ◽

2017 ◽

Vol 177 (2) ◽

pp. 419-427 ◽

Cited By ~ 55

Author(s):

H. Saeki ◽

K. Kabashima ◽

Y. Tokura ◽

Y. Murata ◽

A. Shiraishi ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Phase Ii Study ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽